REPLIGEN CORP
About REPLIGEN CORP
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2017
- $141.2M
- Net income
- $48.9M
- Total assets
- $2.9B
- Market cap
- $6.9B
- Gross margin
- 52.3%
- Operating margin
- 7.5%
- Net margin
- 6.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $738.3M
- Cost of revenue
- $352.0M
- Gross profit
- $386.2M
- Operating expenses
- $331.1M
- Operating income
- $55.2M
- Income tax
- $13.5M
- Net income
- $48.9M
- EPS (basic)
- $0.87
- EPS (diluted)
- $0.86
Balance sheet
- Total assets
- $2.9B
- Current assets
- $1.1B
- Total liabilities
- $843.6M
- Current liabilities
- $135.8M
- Shareholders’ equity
- $2.1B
Cash flow
- Operating cash flow
- $117.4M
- Investing cash flow
- -$298.5M
- Financing cash flow
- -$15.2M
- Net cash flow
- -$196.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.9B
- P/E ratio
- 145.7
- EPS (diluted)
- $0.86
- Shares outstanding
- 55.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 29, 1986
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $48.9M in FY2017.
- Revenue grew 10% from FY2021 to FY2025.
- Gross margin of 52.3%, net margin 6.6%.
- Trading 27% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 145.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review REPLIGEN CORP.
Write a review
News about REPLIGEN CORP
News & sentiment via Polygon.io
